Among all countries worldwide those in sub-Saharan Africa have the highest rates of HIV. The countries with the highest rates of HIV include Eswatini, Lesotho, and South Africa. In 2023, Eswatini had the highest prevalence of HIV with a rate of around ** percent. Other countries, such as Zimbabwe, have significantly decreased their HIV prevalence. Community-based HIV services are considered crucial to the prevention and treatment of HIV. HIV Worldwide The human immunodeficiency virus (HIV) is a viral infection that is transmitted via exposure to infected semen, blood, vaginal and anal fluids and breast milk. HIV destroys the human immune system, rendering the host unable to fight off secondary infections. Globally, the number of people living with HIV has generally increased over the past two decades. However, the number of HIV-related deaths has decreased significantly in recent years. Despite being a serious illness that affects millions of people, medication exists that effectively manages the progression of the virus in the body. These medications are called antiretroviral drugs. HIV Treatment Generally, global access to antiretroviral treatment has increased in recent years. However, despite being available worldwide, not all adults have access to antiretroviral drugs. Europe and North America have the highest rates of antiretroviral use among people living with HIV. There are many different antiretroviral drugs available on the market. As of 2024, ********, an antiretroviral marketed by Gilead, was the leading HIV treatment based on revenue.

The average for 2022 based on 48 countries was 3.95 percent. The highest value was in Swaziland: 25.9 percent and the lowest value was in Algeria: 0.1 percent. The indicator is available from 1990 to 2022. Below is a chart for all countries where data are available.

The states with the highest rates of HIV diagnoses in 2022 included Georgia, Louisiana, and Florida. However, the states with the highest number of people with HIV were Texas, California, and Florida. In Texas, there were around 4,896 people diagnosed with HIV. HIV/AIDS diagnoses In 2022, there were an estimated 38,043 new HIV diagnoses in the United States, a slight increase compared to the year before. Men account for the majority of these new diagnoses. There are currently around 1.2 million people living with HIV in the United States. Deaths from HIV The death rate from HIV has decreased significantly over the past few decades. In 2023, there were only 1.3 deaths from HIV per 100,000 population, the lowest rate since the epidemic began. However, the death rate varies greatly depending on race or ethnicity, with the death rate from HIV for African Americans reaching 19.2 per 100,000 population in 2022, compared to just three deaths per 100,000 among the white population.

United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.500 % in 2014. This stayed constant from the previous number of 0.500 % for 2013. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.500 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.500 % in 2014 and a record low of 0.500 % in 2014. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.; ; UNAIDS estimates.; Weighted Average;

In 2022, it was estimated that around **** percent of Botswana's population aged 15-49 years was infected with HIV. This statistic shows the ** countries with the highest prevalence of HIV worldwide as of 2022.

As of 2023, South Africa was the country with the highest number of people living with HIV in Africa. At that time, around 7.7 million people in South Africa were HIV positive. In Mozambique, the country with the second-highest number of HIV-positive people in Africa, around 2.4 million people were living with HIV. Which country in Africa has the highest prevalence of HIV? Although South Africa has the highest total number of people living with HIV in Africa, it does not have the highest prevalence of HIV on the continent. Eswatini currently has the highest prevalence of HIV in Africa and worldwide, with almost 26 percent of the population living with HIV. South Africa has the third-highest prevalence, with around 18 percent of the population HIV positive. Eswatini also has the highest rate of new HIV infections per 1,000 population worldwide, followed by Lesotho and South Africa. However, South Africa had the highest total number of new HIV infections in 2023, with around 150,000 people newly infected with HIV that year. Deaths from HIV in Africa Thanks to advances in treatment and awareness, HIV/AIDS no longer contributes to a significant amount of death in many countries. However, the disease is still the fourth leading cause of death in Africa, accounting for around 5.6 percent of all deaths. In 2023, South Africa and Nigeria were the countries with the highest number of AIDS-related deaths worldwide with 50,000 and 45,000 such deaths, respectively. Although not every country in the leading 25 for AIDS-related deaths is found in Africa, African countries account for the majority of countries on the list. Fortunately, HIV treatment has become more accessible in Africa over the years and now up to 95 percent of people living with HIV in Eswatini are receiving antiretroviral therapy (ART). Access to ART does vary from country to country, however, with around 77 percent of people who are HIV positive in South Africa receiving ART, and only 31 percent in the Congo.

According to Cognitive Market Research, the global HIV drugs market size will be USD 35425.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.80% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 14170.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.0% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 10627.56 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 8147.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 1771.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 708.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.
The multi-class combination drugs held the highest HIV drugs market revenue share in 2024.

Market Dynamics of HIV drugs Market

Key Drivers for HIV drugs Market

Rising number of HIV-positive individuals to Increase the Demand Globally

The HIV drugs market has experienced growth due to rising number of HIV-positive individuals. As global HIV prevalence increases due to factors like higher transmission rates and improved diagnostic capabilities, demand for effective antiretroviral therapies (ART) surges. This growing patient base necessitates the continuous development and supply of innovative drugs to manage HIV effectively, reduce viral loads, and improve quality of life. Increased awareness and testing also contribute to higher diagnosed cases, further expanding the market for HIV treatments and driving pharmaceutical companies to invest in research and development.

Innovations in HIV diagnostic tools to Propel Market Growth

The HIV drugs market has witnessed steady growth, driven by innovations in HIV diagnostic tools. Advances include rapid, point-of-care tests that deliver results within minutes, improving patient access and reducing diagnostic delays. Integrated technologies, such as multiplex assays, detect multiple markers simultaneously, increasing diagnostic accuracy. Additionally, digital platforms for data management streamline monitoring and personalized treatment plans. These innovations not only improve patient outcomes but also stimulate demand for more effective HIV treatments and management solutions, fostering market growth.

Restraint Factor for the HIV drugs Market

High cost of HIV treatment to Limit the Sales

The high costs of HIV medications constrain the growth of HIV drugs market. It involves expensive medications that can be unaffordable for many patients, especially in low-income regions. The costs are compounded by the need for lifelong treatment, regular monitoring, and potential side effects management, which further burdens healthcare systems and patients. This financial barrier limits access to effective treatment, leading to disparities in care and hindering efforts to control the HIV epidemic globally.

Impact of Covid-19 on the HIV drugs Market

The Covid-19 significantly impacted the market by disrupting supply chains, leading to delays in drug production and distribution, increasing lockdowns and restrictions. Additionally, the focus on COVID-19 diverted resources away from HIV programs, affecting drug availability and patient adherence. However, the pandemic also accelerated the adoption of telemedicine and digital health solutions, which helped maintain patient care continuity. Overall, the pandemic highlighted the need for resilient healthcare systems in managing chronic diseases. Introduction of the HIV drugs Market

HIV drugs are medications used to treat Human Immunodeficiency Virus (HIV) infection. They work by suppressing the virus, preventing its replication, and protecting the immune system. These drugs are typically used in combination as antiretroviral therapy (ART) to reduce viral load, improve patient outcomes, and prevent the progression to AIDS. The rising number of HIV-positive individuals, advancemnets in drug development, increasing government initiatives and funding, increased aw...

In 2024, in South Africa, there were around 3.1 HIV newly infected persons per every 1,000 inhabitants. This statistic depicts the countries with the highest incidence rates of new HIV infections worldwide as of 2024.

According to Cognitive Market Research, the global HIV Diagnostics market size is USD 4158.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 10.90% from 2024 to 2031. North America held the major market share for more than 40% of the global revenue with a market size of USD 1663.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031. Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1247.46 million. Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 956.39 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031. Latin America had a market share of more than 5% of the global revenue with a market size of USD 207.91 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.3% from 2024 to 2031. Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 83.16 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.6% from 2024 to 2031. Consumables held the highest HIV Diagnostics market revenue share in 2024. Market Dynamics of HIV Diagnostics Market Key Drivers for HIV Diagnostics Market Increasing Prevalence of Sexually Transmitted Disease to Increase the Demand Globally Throughout the many decades of the HIV pandemic, the number of infected individuals is continually rising. The socioeconomic variables driving this continuous increase also suggest that preventative measures have not been successful. Even though many of these infections are preventable, there are an estimated 20 million new cases of STDs in the US each year, and the rate is still rising. Moreover, there are over 1.2 million HIV-positive individuals residing in the United States. Attempts to encourage testing and screening for sexually transmitted infections can ascertain an individual's likelihood of acquiring one and help those who already have one receive treatment, so enhancing their health and lowering the danger of HIV spreading to others. Approximately 38.4 million people worldwide were HIV positive in 2021. Among these, women and girls made up nearly 54%. Rising Initiatives by Global Agencies to Propel Market Growth HIV is among the world's most important public health concerns. As a result, there is a global commitment to stopping new HIV infections and giving everyone on the planet access to HIV therapy. WHO recommends testing for HIV to anyone who might be at risk. The World Bank was a leader in global financing for HIV/AIDS in the early phases of the pandemic and has contributed US$4.6 billion to programs related to the illness since 1989. Because of assistance from the Bank—more precisely, through the International Development Association—for 1,500 counseling and testing centers, about 7 million people have had HIV tests. Restraint Factor for the HIV Diagnostics Market Lack of Healthcare Infrastructure and Awareness to Limit the Sales A proper infrastructure for healthcare delivery is lacking in many areas, especially in poor nations, which makes it difficult to provide diagnostic services. This covers concerns with the supply chain, inadequate laboratory facilities, and skilled staff. It might be particularly difficult to access diagnostic services in rural and isolated places due to a lack of healthcare facilities and inadequate transportation infrastructure. Furthermore, HIV diagnosis rates are lower in the developing Asia-Pacific, Middle East, and African regions. These areas require a sufficient number of diagnostic facilities. Additionally, the diagnosis process needs to be explained to the majority of patients, which restricts market growth in these areas. Impact of Covid-19 on the HIV Diagnostics Market The COVID-19 pandemic has had a significant impact on the HIV diagnostics market, both in terms of challenges and opportunities. There was a decrease in HIV testing and diagnostic services during the pandemic as a result of the extensive healthcare resources being redirected to handle COVID-19. Some facilities were converted to provide COVID-19 treatment, and clinics and labs had a staffing crisis. Reduced HIV testing rates were the outcome of routine and community-based HIV testing programs being frequently halted to stop the spread of COVID-19. The adoption of telemedicine and remote healthcare services was expedited by the epidem...

Mexico MX: Prevalence of HIV: Male: % Aged 15-24 data was reported at 0.200 % in 2017. This stayed constant from the previous number of 0.200 % for 2016. Mexico MX: Prevalence of HIV: Male: % Aged 15-24 data is updated yearly, averaging 0.200 % from Dec 1990 (Median) to 2017, with 28 observations. The data reached an all-time high of 0.200 % in 2017 and a record low of 0.100 % in 2009. Mexico MX: Prevalence of HIV: Male: % Aged 15-24 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Mexico – Table MX.World Bank.WDI: Health Statistics. Prevalence of HIV, male is the percentage of males who are infected with HIV. Youth rates are as a percentage of the relevant age group.; ; UNAIDS estimates.; Weighted average; In many developing countries most new infections occur in young adults, with young women being especially vulnerable.

The average for 2022 based on 9 countries was 0.48 percent. The highest value was in Thailand: 1.1 percent and the lowest value was in India: 0.2 percent. The indicator is available from 1990 to 2022. Below is a chart for all countries where data are available.

In 2022, the states with the highest number of HIV diagnoses were Texas, California, and Florida. That year, there were a total of around 37,601 HIV diagnoses in the United States. Of these, 4,896 were diagnosed in Texas. HIV infections have been decreasing globally for many years. In the year 2000, there were 2.8 million new infections worldwide, but this number had decreased to around 1.3 million new infections by 2023. The number of people living with HIV remains fairly steady, but the number of those that have died due to AIDS has reached some of its lowest peaks in a decade. Currently, there is no functional cure for HIV or AIDS, but improvements in therapies and treatments have enabled those living with HIV to have a much improved quality of life.

United Arab Emirates AE: Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.130 Ratio in 2020. This records an increase from the previous number of 0.120 Ratio for 2019. United Arab Emirates AE: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.020 Ratio from Dec 1990 (Median) to 2020, with 31 observations. The data reached an all-time high of 0.130 Ratio in 2020 and a record low of 0.010 Ratio in 2004. United Arab Emirates AE: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Arab Emirates – Table AE.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].

HIV Test Kits Market Outlook

The global HIV test kits market size was estimated to be approximately USD 2.3 billion in 2023 and is expected to reach USD 4.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.8% from 2024 to 2032. The rise in market size can be primarily attributed to the increasing awareness of HIV prevention and management, advancements in testing technologies, and the growing demand for quick and accurate diagnostic solutions. Additionally, governmental and non-governmental initiatives across the world to combat HIV/AIDS have significantly propelled the market forward.

In recent years, the HIV test kits market has seen a substantial growth spur due to the heightened global focus on early diagnosis and treatment of HIV. With health organizations emphasizing test-and-treat strategies, the demand for efficient and accessible testing methods has surged. The development of new testing technologies that offer rapid and accurate results has further fueled this growth. Additionally, the destigmatization of testing and the increasing availability of home test kits have empowered individuals to take charge of their health, contributing to market expansion. Furthermore, collaborations between governments and healthcare institutions in underdeveloped regions to provide affordable testing solutions are playing a critical role in driving market growth.

The burgeoning demand for HIV test kits is also driven by the escalating prevalence of HIV infection across various demographics. Efforts to curb the spread of the virus have led to extensive awareness programs and educational campaigns promoting regular testing. As healthcare systems recognize the cost-effectiveness of early detection, investments in the development and distribution of test kits are increasing. Moreover, technological advancements in test kits, such as enhanced sensitivity and specificity in rapid tests, are attracting a broader user base. The integration of digital technologies and mobile health solutions is also revolutionizing the market landscape, making testing more convenient and widespread.

Another significant growth factor is the rising inclination towards personalized healthcare and the shift from centralized to decentralized testing approaches. Home testing kits have gained popularity owing to their convenience and privacy, enabling individuals to test themselves without the need for professional assistance. The ease of access to these kits through online channels and pharmacies has broadened the market scope. Moreover, regulatory agencies globally are streamlining approval processes for innovative test kits, thus encouraging manufacturers to invest in research and development. This environment fosters innovation and expansion in the HIV test kits market, with an emphasis on improving accuracy, affordability, and user-friendliness.

The introduction of STD Rapid Test Kits has revolutionized the landscape of sexually transmitted disease diagnostics, offering a swift and reliable method for detecting infections. These kits are designed to provide quick results, often within minutes, which is crucial for timely intervention and treatment. The convenience and accessibility of these kits have made them a popular choice for both healthcare providers and individuals seeking discreet testing options. As the demand for rapid diagnostics grows, the market for STD Rapid Test Kits is expected to expand, driven by technological advancements and increased awareness of sexual health. The integration of these kits into routine healthcare practices not only enhances early detection but also plays a vital role in controlling the spread of infections, ultimately contributing to improved public health outcomes.

Regionally, North America and Europe dominate the HIV test kits market due to advanced healthcare infrastructure and high awareness levels. However, Asia Pacific is expected to witness the highest growth rate during the forecast period, driven by increasing government initiatives and a rising number of HIV cases. In contrast, Africa remains a critical region due to its high HIV prevalence, where efforts are being made to enhance access to testing and treatment. The region's strategic importance lies in the potential reduction of disease burden through the implementation of widespread testing programs. This regional momentum aligns with global strategies to end the HIV epidemic, marking significant progress in the market.

Product Type Analysis

The HIV

This statistic describes the countries with the highest number of new HIV infections around the world in 2015. In that year, there were some 380 thousand new HIV infections reported from South Africa.

Laos LA: Incidence of HIV: per 1,000 Uninfected Population Aged 15-24 data was reported at 0.300 Ratio in 2022. This stayed constant from the previous number of 0.300 Ratio for 2021. Laos LA: Incidence of HIV: per 1,000 Uninfected Population Aged 15-24 data is updated yearly, averaging 0.330 Ratio from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 0.360 Ratio in 2009 and a record low of 0.010 Ratio in 1991. Laos LA: Incidence of HIV: per 1,000 Uninfected Population Aged 15-24 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Laos – Table LA.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations ages 15-24 expressed per 1,000 uninfected population ages 15-24 in the year before the period.;UNAIDS estimates.;Weighted average;This is an age-disaggregated indicator for Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].

Prevalence of HIV, male (% ages 15-24) in Ghana was reported at 0.3 % in 2022, according to the World Bank collection of development indicators, compiled from officially recognized sources. Ghana - Prevalence of HIV, male (% ages 15-24) - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.

The average for 2022 based on 12 countries was 0.67 percent. The highest value was in Suriname: 1.6 percent and the lowest value was in Argentina: 0.4 percent. The indicator is available from 1990 to 2022. Below is a chart for all countries where data are available.

Romania RO: Incidence of HIV: per 1,000 Uninfected Population Aged 15-24 data was reported at 0.020 Ratio in 2022. This stayed constant from the previous number of 0.020 Ratio for 2021. Romania RO: Incidence of HIV: per 1,000 Uninfected Population Aged 15-24 data is updated yearly, averaging 0.030 Ratio from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 0.030 Ratio in 2016 and a record low of 0.010 Ratio in 1994. Romania RO: Incidence of HIV: per 1,000 Uninfected Population Aged 15-24 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Romania – Table RO.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations ages 15-24 expressed per 1,000 uninfected population ages 15-24 in the year before the period.;UNAIDS estimates.;Weighted average;This is an age-disaggregated indicator for Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].

Azerbaijan Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.050 Ratio in 2022. This stayed constant from the previous number of 0.050 Ratio for 2021. Azerbaijan Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.060 Ratio from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 0.110 Ratio in 2004 and a record low of 0.010 Ratio in 1993. Azerbaijan Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Azerbaijan – Table AZ.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].